
UNCLASSIFIED



Joint Program Executive Office for Chemical and Biological Defense Medical Virtual Industry Day



Kevin Carlton
Vaccine Manager
Joint Vaccine Acquisition Program
301.619.8437

November 15, 2012















Distribution Statement A: Approved for public release; distribution is unlimited.



Disclaimer



- While we are presenting our currently planned Business Opportunities, we recognize that these may change given our changing fiscal environment and the strategic guidance of the Department of the Defense.
- New starts and increases to production levels in FY13 will be delayed until the Appropriations Bill is passed.



Capability Gap & Product Description



Capability Gap:

 There are no FDA-approved prophylactic or antiviral medical countermeasures against Western, Eastern and Venezuelan Equine Encephalitis Virus

Product Description:

FDA approved trivalent vaccine that will protect against aerosolized exposure to WEEV, EEEV, and VEEV





Product Fit in the Family of Systems



 The WEVEE vaccine is part of a family of systems that protect the Warfighter from biological warfare





WEVEE Product Schedule



Western Eastern Venezuelan Equine Encephalitis Vaccine (WEVEE) Schedule																																
	PRIOR				FY12			FY13				FY14				FY15				FY16					FY17				FY18			
	FY08 FY09	FY10	FY11	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	
Milestones &					4			ļ	+				Technology I			Development Phase												•				
Phases					MDD				MS A																						Pr∉- EMD	
Source Selection & Contract(s) Activities					RFI								RFP		Contr Awa	act rd													F	RFI	RF	
Capabilities Documents S	CD ept 004								Draft CDD			-																			CDC	
Reviews and Audits								AoA														Pre-IN Meeti	ID ng			Subi	IND missio	on				
Manufacturing Activities										Challenge I			erial			Proce	rocess and Formulat Development		ion		GMF		MFG					Stability Testing				
Testing											Proo	f of Co Efficad	Concept acy			E	xpand an	led no	on-clin nunog	nical e genici	cal efficacy GLP enicity Te				Toxicity esting			Phase 1 Clinical Trial				

- Program Initiation at Milestone A in 2QFY13
- RFP Solicitation in 1QFY14 includes
 - Process and Formulation Development
 - GMP manufacturing
 - Stability Testing
- RFP Solicitation at Pre-EMD in 4QFY18 for Prime Systems Contractor



Strategy:

Leverage current contracts and Interagency collaborations to evaluate multiple prototypes in the Technology Development Phase

Status:

- Milestone A to Milestone B
 - JVAP will serve as the integrator
 - Government will serve as Regulatory Sponsor
 - RFP for Manufacturing following MS A (2QFY14)
- Milestone B to Licensure
 - Prototype down select at MS B
 - RFP for Prime Systems Contractor at Pre-EMD (4QFY18)
 - To include procurement options
 - Prime Systems Contractor will serve as Regulatory Sponsor



- There are no FDA-approved products to provide protection against an aerosol or endemic exposure
- Current IND products have poor tolerability and efficacy limitations against aerosol exposure
- Animal models are immature for both small and large animal models



- Anticipated 4QFY14 contract award for manufacturing
 - Released Request for Information 16 Aug 12 Process development and manufacturing of VLP, VRP, and/or DNA Vaccines
 - Anticipate Request for Proposal release 2QFY14
- Explore opportunities for animal model development, analytical assay development, and competitive prototyping through task order vehicles, CBMS BAA, and Interagency collaborations
 - Small animal model development and qualification
 - Passive transfer and correlates of protection assay development
 - Advanced development studies to evaluate WEVEE vaccine prototypes



Points of Contact





Learn how we partner with industry, other government agencies and academia. www.jpeocbd.osd.mil/packs/Default.aspx?pg=1207



LIKE US

Use your smartphone to scan our QR code and go directly to our website





Acronym Glossary



ADM: Acquisition Decision Memorandum or Advanced Development & Manufacturing

AoA: Analysis of Alternatives

APUC: Acquisition Procurement Unit Cost

AS: Acquisition Strategy

BARDA: Biomedical Advanced Research and

Development Authority **BBP:** Better Buying Power

BLA: Biologics License Application

BSV: Biosurveillance

CBMS: Chemical Biological Medical Systems **CDD:** Capability Development Document

CPD: Capability Production Document

cGMP: Current Good Manufacturing Practice

CONOPS: Concept of Operations **CPIF:** Cost Plus Incentive Fee

DARPA: Defense Advanced Research Projects

Agency

DHS: Department of Homeland Security

DoD: Department of Defense

DSTL: Defense Science Technology Laboratory

DTRA/JSTO: Defense Threat Reduction Agency/Joint Science and Technology Office

EMD: Engineering Manufacturing and

Development

EPA: Environmental Protection Agency **FDA:** US Food & Drug Administration

FFP: Fixed Firm Price

FOC: Full Operational Capability

FRP: Full Rate Production

FY: Fiscal Year

HHS: Health and Human Services

IBR: Integrated Baseline Review

ICD: Initial Capabilities Document

IND: Investigational New Drug

IOC: Initial Operational Capability

JILA: Joint Integrated Logistics Assessment

JPEO: Joint Program Executive Office(r)

JPM: Joint Project/Product Manager

JPM-ADM: Joint Project Manager- Advanced

Development & Manufacturing

JPMO: Joint Project/Product Management Office

JRO-CBRND: Joint Requirements Office for Chemical, Biological, Radiological, and

Nuclear Defense

JVAP: Joint Vaccine Acquisition Program

KPP: Key Performance Parameter

KSA: Key System Attribute

LCCE: Life Cycle Cost Estimate

LCMP: Life Cycle Management Plan **LCSP:** Life Cycle Sustainment Plan

LRIP: Low Rate Initial Production

MDA: Milestone Decision Authority

MITS: Medical Identification and Treatment

Systems MS: Milestone

MSR: Manufacturing Sustainment Rate

NDA: New Drug Application

NGDS: Next Generation Diagnostic System

NIH: National Institutes of Health **NTA:** Non-Traditional Agent

O&M: Operation and Maintenance

OASD (HA): Office of the Assistant Secretary of

Defense (Health Affairs)

OGA: Other Government Agency

OSD (NCB/CB): Office of the Secretary of Defense (Nuclear/Chemical Biological)

OSTP: Office of Science and Technology Policy

OUSD(C): Office of the Under Secretary of

Defense (Comptroller)

PAIO: Joint CBRN Defense Program Analysis Integration Office

RDT&E: Research, Development, Test and Evaluation

RFP: Request For Proposal

SEP: Systems Engineering Plan

SNS: Strategic National Stockpile

SPA: Special Protocol Assessment

TD: Technology Development **TDP:** Technical Data Package

TED: Troop Equivalent Dose

THP: Trained Health Care Provider

TMT: Transformational Medical Technologies

TOA: Total Obligation Authority

TRA: Technology Readiness Assessment

TRL: Technology Readiness Level

USAMMDA: US Army Medical Materiel

Development Activity

USAMRIID: US Army Medical Research Institute

of Infectious Disease

USAMRICD: US Army Medical Research Institute

of Chemical Defense

USAMRMC: US Army Medical Research and

Materiel Command